Subscription Center
Apr 16, 2009 02:45 PM
Pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer said today that they're creating a company dedicated to developing HIV medications. The unusual arrangement will give London-based GSK 85 percent equity and New York's Pfizer the remainder.
The companies said in a statement that the merger would "be more sustainable and broader in scope than either company's individually," giving the new partnership 19 percent of the HIV drug market through a combined portfolio of 11 already-available meds and six candidates in development. The idea is that the $2.4 billion in sales generated from the marketed drugs will keep the development pipeline moving, the companies said.
GSK's vaccine development won't be part of the new company, according to Bloomberg News.
The deal helps GSK because its HIV drugs are old (and approaching patent expiration) and its own development pipeline is thin, the Wall Street Journal notes. Pfizer, on the other hand, has more robust drug candidates but fewer meds on the market, according to the Associated Press.
Still, Gilead Sciences, based in Foster City, Calif., now dominates the HIV drug market.
"We continue expect Gilead to remain a step ahead of the competition and view the new company as another example of a pharma merger driven by weakness," M. Ian Somaiya, an analyst at Thomas Weisel Partners, wrote in a note to clients, Bloomberg News notes.
Image © iStockphoto/rocksunderwater
Tags:
vaccines,
drugs,
AIDS,
HIV
More News Blog:
Next: Spammers be damned: Junk e-mail is a huge waste of energy
Previous: High-speed rail getting on track in the U.S.
See what we're tweeting about
EricROlson Daniel Dennett's seven tools for thinking http://t.co/Bo2NNjtHWS
Myrmecos You don't need expensive gear to take great insect photos. Derek Hauffe uses an old Canon digicam, and look! https://t.co/dGYFRPAGhl
JenLucPiquant Revenge, ego and the corruption of Wikipedia: writer took advantage of online anonymity to pursue old vendettas http://t.co/CEQtAcg8Us
Deadline: Jul 25 2013
Reward: Varies
This challenge provides an opportunity for Solvers to build a web-based or mobile “app” to explore data relationships in scholarly conte
Deadline: Jul 30 2013
Reward: $100,000 USD
The Seeker desires a method for producing pseudoephedrine products in such a way that it will be extremely difficult for clandestine che
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
Comments
Add Comment